[Recent developments in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)]

Area of Science:

• Oncology
• Urology
• Pharmacology

Background:

• Advanced prostate cancer therapy has seen progress, yet effective treatments for metastatic hormone-sensitive prostate cancer (mHSPC) remain a challenge.
• A significant unmet medical need exists for safe and efficacious therapies applicable to a wide range of mHSPC patients.

Purpose of the Study:

• To evaluate the efficacy and safety of apalutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC).
• To assess the impact of apalutamide plus ADT on patient quality of life.

Main Methods:

• The pivotal TITAN study investigated apalutamide plus ADT versus placebo plus ADT in patients with mHSPC.
• Patient inclusion criteria were broad, encompassing individuals regardless of risk, disease volume, or time of diagnosis.

Main Results:

• Apalutamide in combination with ADT demonstrated significant efficacy and a favorable safety profile compared to placebo.
• The combination therapy maintained patient quality of life.
• The TITAN study's findings support apalutamide's use in a diverse mHSPC patient group.

Conclusions:

• Apalutamide plus ADT has successfully addressed the unmet medical need for effective mHSPC treatments since its 2020 label extension.
• The therapy is suitable for a wide patient population, including those with varying risk profiles and disease characteristics.